Search Results 61-70 of 982 for ���������������������������������������������:PC90���

  1. https://www.mayoclinic.org/spanish_procedure_concepts.xml

  2. A Study to Evaluate Posoleucel ALVR105 to Treat Kidney Transplant Recipients with BK Viremia - Mayo Clinic

    The key secondary objective is to test the hypothesis that the administration of posoleucel ALVR105 to kidney transplant recipients with BK viremia will ...

  3. An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738) - Mayo Clinic

    The purpose of Part I of the study is to assess the efficacy and safety of MK-8931 compared with placebo administered for 78 weeks in the treatment of ...

  4. Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) - Mayo Clinic

    Clinical Trials · Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) · More about research at ...

  5. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis - Mayo Clinic

    TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor- ...

  6. https://www.mayoclinic.org/arabic_patient_consumer_faq.xml

  7. An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia - Mayo Clinic

    placebo with azacitidine (AZA) as background therapy in patients ≥ 18 years of age with newly diagnosed acute myeloid leukemia (AML), excluding acute ...

  8. https://www.mayoclinic.org/spanish_patient_consumer_faq.xml

  9. https://www.mayoclinic.org/chinese_procedure_concepts.xml

  10. A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma - Mayo Clinic

    The purpose of the phase 2 portion is to estimate the PFS of patients with advanced soft tissue sarcoma by RECIST 1.1. Participation eligibility. Participant ...